Portal de Periódicos da CAPES

Classification of diseases with accumulation of Tau protein

2022; Wiley; Volume: 48; Issue: 3 Linguagem: Inglês

10.1111/nan.12792

1365-2990

Gábor G. Kovács, Bernardino Ghetti, Michel Goedert,

S100 Proteins and Annexins

Abnormal filaments of known composition in neurons and glia define many sporadic and hereditary human neurodegenerative diseases. The pathogenic significance of filamentous inclusions became evident when cases of dominantly inherited disease were shown to be associated with mutations in the genes encoding the proteins that make up filaments, be they Tau [1-3], Aβ [4, 5], α-synuclein [6], prion protein [7], TDP-43 [8-10] or FUS [11, 12]. By extrapolation, it follows that a gain-of-toxic function resulting from the ordered assembly into filaments may also underlie sporadic forms of disease. Assemblies of the microtubule-associated protein Tau into filaments characterise many neurodegenerative diseases. In humans, MAPT, the gene encoding Tau protein, generates six isoforms (352–441 amino acids) by alternative mRNA splicing [13]. They differ by the presence or absence of three inserts encoded by exons 2, 3 and 10. Inclusion of exon 10 results in the production of three isoforms with four C-terminal repeats (each repeat is 31 or 32 amino acids long) (4R) and its exclusion in another three isoforms with three repeats (3R). Diseases characterised by the intracellular accumulation of Tau filaments can be divided into three groups, based on the isoform composition of filaments (3R, 4R, 3R + 4R) [14]. In these diseases, be they sporadic or inherited, Tau is extensively modified post-translationally [15-17]. Tauopathy was coined to describe a dominantly inherited neurodegenerative disease with a +3 mutation in intron 10 of MAPT and abundant filamentous inclusions made of 4R Tau [3, 18]. However, this term is also used in neuropathology and neuroscience to refer to the mere presence of Tau in tissues. The terms primary and secondary tauopathies are also being used [19-25], even though mutations in MAPT are the only known aetiology for Tauopathies. Primary tauopathy refers to conditions where the presence of Tau filaments is the main or sole known abnormality or where tau pathology is considered the major contributing factor to neurodegeneration interpreted as main 'driving force of pathogenesis', as opposed to other proteins such as Aβ [23, 25-28]. Primary tauopathies are also included in the group of frontotemporal lobar degeneration (FTLD). The latter is characterised by the predominant atrophy of frontal and temporal lobes of the cerebral cortex and occurs in association with several different proteinopathies [29]. Secondary tauopathy is used when additional 'driving pathogenic forces' are believed to be involved [19]. In our view, cases with mutations in MAPT are the only known example of a primary tauopathy, whereas familial Alzheimer's disease may be secondary tauopathy. These terms should not be used when referring to diseases of unknown aetiology. Diseases with pathologic Tau can be classified on the basis Tau isoforms, 3R, 4R or both 3R and 4R being demonstrable with isoform-specific antibodies or Western blot patterns of sarkosyl-insoluble Tau. The anatomical distribution, along with the histological and cytological characterisation of neuronal and glial tau immunoreactivities, is also needed for clinicopathological classification [19, 20, 30]. Formation of abnormal Tau filaments is a central event in several neurodegenerative diseases. Like the filaments of other pathologic amyloids, Tau filaments have a cross-β conformation [31]. Recently, the Tau folds of Alzheimer's disease [32, 33], Pick's disease [34], chronic traumatic encephalopathy (CTE) [35], corticobasal degeneration (CBD) [36, 37], argyrophilic grain disease (AGD), progressive supranuclear palsy (PSP) and globular glial tauopathy (GGT) [38] were shown to be different. The Tau filament fold of primary age-related tauopathy (PART) was identical to the Alzheimer fold, indicating that it can form in the absence of Aβ deposits [39]. The same filament structures have been found for different individuals with a given disease. It is also noteworthy that Tau folds identical to those of Alzheimer's disease coexisted with cerebral parenchymal Aβ amyloid, PrP amyloid, Abri and ADan amyloid [38, 40]. Tau filament structures from the brains of intron 10 MAPT mutation carriers were identical to those of AGD. Structural analysis of tau filament folds has also led to the discovery of potentially new disease entities [38]. It is now timely to update the existing terminology and re-examine the grouping of disorders associated with intracellular tau accumulation, because (1) there is an increased interest in the role of Tau assembly in neurodegeneration, (2) inconsistent terminology has been used and (3) high-resolution tau filament structures have been determined. Here, we put forward definitions of terms to describe Tau in various conditions, as well as a simple and flexible stratification system that will also allow inclusion of novel pathological entities. Identification of high-resolution Tau filament structures from brain has provided a compelling argument for reconsidering nomenclature and group organisation of conditions in which tau assembly is believed to play a role. Because the term 'tauopathy' has not been rigorously defined, there is a need to establish its precise meaning, so as to avoid inconsistent use. This term implies the presence of assembled Tau through the interpretation of results obtained using at least one of the following: silver staining, immunohistochemistry, immunofluorescence, electron microscopy, immunoblotting and seeding. Tau pathology describes lesions, not clinicopathological entities. This definition acknowledges that each condition is characterised by a spectrum of regional load of filamentous tau deposits (i.e. stages of sequential involvement of brain regions), thus implying that early disease stages may be recognisable in a given disorder. Therefore, early stages of a Tauopathy may be described as Tau pathology. In summary, (1) cellular immunoreactivities are described as 'Tau immunoreactivity' in neurons, astrocytes, oligodendrocytes, etc.; (2) 'Tau pathology', but not 'Tauopathy', should be used for the definition of lesions revealed by routine diagnostic immunohistochemistry; (3) a condition should not be considered a 'Tauopathy' until a consistent staining pattern can be demonstrated in additional cases of disease. We propose the following approach for categorising conditions associated with intracellular Tau accumulation or Tau immunoreactivity of unknown relevance into six groups. It requires knowledge of the following: aetiology, if known, presence of Tau-only pathology vs coexistence with a parenchymal amyloid made of a protein other than Tau and role of assembled Tau in disease pathogenesis. Each group can then be subdivided according to the Tau isoforms involved, as demonstrated by immunostaining and/or immunoblotting using well-characterised 3R and 4R Tau-specific antibodies. In the absence of such knowledge, we say 'awaiting isoform classification'. It follows that Tauopathy conditions can be defined on the basis of the spectrum of specific morphological changes, their clinicopathological phenotypes and historically assigned disease names. Finally, based on the cryo-EM structures of Tau folds, Tauopathies can be classified further [38]. Our knowledge of filament folds is still evolving, and cryo-EM may lead to the identification of novel Tau folds in previously unrecognised conditions. Rather than divide disorders into primary and secondary Tauopathies, we propose to classify Tauopathies into five different groups (Table 1). Group 1 includes cases with mutations in MAPT. Some clinicopathological phenotypes and filament structures may be similar to those in sporadic forms of disease [38, 43]. Group 2 includes disorders with filamentous Tau deposits that are pivotal for neuropathological diagnosis and correlate with clinical symptoms and neurodegeneration, but in the absence of mutations in MAPT. Nomenclature of these conditions is based on either clinical presentation (i.e. PSP), anatomical distribution of neurodegeneration (i.e. CBD), morphology of Tau pathologies (i.e. GGT and AGD) or disease eponyms (i.e. Pick's disease). Groups 1 and 2 are summarised as 'main tauopathies' (Figure 1). Group 3 includes filamentous Tau deposits in dominantly inherited diseases with mutations in genes encoding the proteins that make up extracellular filamentous deposits (Aβ, prion protein, Bri). Group 4 includes filamentous Tau deposits in idiopathic forms of Alzheimer's disease. Groups 3 and 4 are summarised as 'extracellular filamentous deposit-related tauopathies' (Figure 1). Group 5 comprises other Tauopathies that may show overlapping features with those of Group 3. However, they are reported less frequently than those of Group 3. Group 6 includes various conditions with Tau immunoreactivity or Tau pathology. In some cases, Tau immunoreactivity has been described, but filamentous Tau inclusions have not been demonstrated. Tau immunoreactivities or tau pathologies can also be observed in individuals who are clinically normal, where they may represent a preclinical stage and/or an early cytopathological phase of fibril formation [27]. We recommend that 'Tau pathology' rather than 'Tauopathy' be used for conditions in which filamentous Tau may be detected, but where the following may constitute an obstacle for a more precise characterisation: (1) Tau cytopathology is inconsistently detected between cases belonging to the same group of conditions; (2) there are only single case reports; (3) the clinical or pathogenic relevance of Tau cytopathology related to the condition is unclear. Moreover, we also include conditions with neurofibrillary tangles in anatomically circumscribed areas and often unrelated to the leading brain lesions, or constellations of Tau pathologies reported in case reports and not compatible with Tauopathies of Groups 1–5. The proposed grouping is summarised in Figure 1. Finally, coexistence of main Tauopathy-like conditions has been described in various disorders with diverse aetiologies (Table 2). However, these conditions can also present without Tauopathy, and the direct relation of the primary disorder to a Tauopathy has not been demonstrated. Young-onset Alzheimer's disease Late-onset Alzheimer's disease Neuro-astroglial Tauopathy variants in the elderly [46-48] Tauopathy with hippocampal 4-repeat Tau immunoreactive spherical inclusions [49-51] or limbic-predominant neuronal inclusion body 4R Tauopathy (LNT) [38] Diffuse NFTs with calcification (Kosaka-Shibayama disease [52] Western Pacific ALS/PDC (Guam, Kii Peninsula) [53-56] Nodding syndrome-related Tauopathy [57]aa Conditional, the spectrum to be defined in future studies. Chronic traumatic encephalopathy (CTE) IgLON5 antibody-related Tauopathy [58]aa Conditional, the spectrum to be defined in future studies. Post-encephalitic parkinsonism [59]aa Conditional, the spectrum to be defined in future studies. Familial behavioural variant frontotemporal dementia associated with astrocyte-predominant Tauopathy [60, 61] Vacuolar Tauopathy in autosomal-dominant VCP hypomorph mutation (D395G) [62] Niemann–Pick disease type C-related tauopathy [63-66]aa Conditional, the spectrum to be defined in future studies. Progressive ataxia and palatal tremor-related Tauopathy (one study 3R + 4R, another study 4R, based on immunostaining, no biochemistry) [67, 68] Subacute sclerosing panencephalitis-related Tauopathy [69-73]aa Conditional, the spectrum to be defined in future studies. Ganglioglioma [110] Meningioangiomatosis [111-113] Hemimegalencephaly [114] Tuberous sclerosis complex [115] Focal cortical dysplasia [115] Huntington's disease: reduction of soluble Tau protein, increase in Tau phosphorylation at some epitopes, reduction of Tau monomers; increase in Tau exon 10 inclusion and upregulation in 4R-Tau protein levels; increase in the 4R:3R ratio and complex pattern of weaker bands of sarkosyl-insoluble Tau [85, 118, 119] PART/AD, AGD or PSP-like pathology associated with multiple system atrophy or Lewy body disorders Pick's disease pathology associated with Lewy body disorders AGD, PSP, CBD, GGT and Pick's disease type pathology associated with AD PART/AD, AGD or PSP-like pathology associated with frontotemporal lobar degeneration/motor neuron disease with TDP-43 proteinopathy PART/AD, ARTAG, PSP or AGD-like pathology in Creutzfeldt–Jakob disease and variably protease-sensitive prionopathy [84, 122] ARTAG in various conditions [123] AGD-like pathology in cerebrotendinous xanthomatosis [124] AGD-like pathology in DOORS (deafness, onychodystrophy, osteodystrophy, intellectual disability and seizures) syndrome [125] PSP-like pathology in myotonic dystrophy type 1 [126] PSP-like pathology in an asymptomatic myotonic dystrophy type I gene mutation carrier and in an individual with mental retardation [127] PSP, AGD and AD-like pathology in LRRK2 [128, 129] PSP-like pathology in PRKN gene variants [130] PART/AD in genetic Creutzfeldt–Jakob disease [84, 92] AD/PART-like pathology in variants of C9ORF72, GRN and SNCA genes [131-137] AD, ARTAG, CTE and PART-like pathology in Huntington's disease [138-140] PSP-like pathology in benign hereditary chorea mapped to chromosome 8q 21.3-q23.3 [141] Pick body pathology in PSEN1 mutation [142, 143] Pick body pathology in C9ORF72 and MAPT A239T variant [144] AD- and AGD-like pathology in spinocerebellar ataxia 31 [145] As a consequence of developments in our understanding of neurodegenerative diseases and their relation to Tau protein, several terms have been generated, which are widely and inconsistently used. We propose a nomenclature of the various groups of diseases involving Tau that are based on the knowledge of aetiology, relation to non-Tau proteinopathies, presence of Tau isoforms, genetics of MAPT and accumulated experience of clinicopathological correlations, further complemented by high-resolution tau filament structures. We propose a simple system that can easily accommodate future discoveries (i.e. disorders can be moved between groups). This will hopefully allow those working on the understanding of the role of Tau in various conditions to communicate their findings in more concise and unambiguous ways and will inform therapeutic developments. GGK is supported by the Rossy Foundation and the Edmond Safra Philanthropic Foundation. MG is supported by the UK Medical Research Council (MC_U105184291). BG is supported by NIH grants (U01 NS110437 and RF1 AG071177-01A1). The authors report no conflicts of interest specific to this manuscript. GGK, BG, and MG all contributed to the design and conception of the paper and wrote the manuscript. The peer review history for this article is available at https://publons.com/publon/10.1111/nan.12792. The peer review history for this article is available at https://publons.com/publon/10.1111/nan.12792.